Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 66Colonic Neoplasms 31Rectal Neoplasms 30Pancreatic Neoplasms 18Stomach Neoplasms 16Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Esophageal Neoplasms 6Leukemia 5Neoplasms 4Lymphoma 4Liver Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma Of Esophagus 3Solid Tumors 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neutropenia 2Leukemia, Biphenotypic, Acute 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Colorectal Cancer Metastatic 2Carcinoma, Squamous Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Bile Duct Neoplasms 2mCRC 1Unresectable Sinonasal Tumors 1Thymoma 1Small Cell Lung Carcinoma 1

Interventions

S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × mCRC × Leucovorin × Clear all
NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡